Loading stock data…
KLRA
$19.49-0.15 (-0.76%)
Market OpenUpdated 1:30 PM EDT
Kailera Therapeutics, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$84.66M↓ | -$20.46M |
| Net Income | -$78.86M↓ | -$17.98M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectabl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.54B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.41%
Volume
Today's trading volume
152,048
Recent News
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
On Tuesday, William Blair initiated coverage on Kailera Therapeutics Inc. (NASDAQ:KLRA), the latest entrant in the fast-growing weight-loss drug market. The obesity-focused biotech raised more than $600 million in April through an initial public offering of 39.06 million shares priced at $16 each. Kailera Portfolio ‘Strongly Mirrors’ Eli Lilly William Blair analyst Andy Hsieh said Kailera’s obesity pipeline could position the company as a future challenger in the expanding weight-loss market, ci
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity
Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.
Kailera IPO And Governance Overhaul Set Terms For NASDAQ Composite Debut
Kailera Therapeutics (NasdaqGS:KLRA) completed its initial public offering, moving from private to public ownership. Alongside the IPO, the company adopted an amended and restated certificate of incorporation and new bylaws that reshape its governance framework. The governance changes include a classified board of directors, authorization of preferred stock, and defined procedures for shareholder actions. Kailera Therapeutics was added to the NASDAQ Composite Index, bringing the stock into a...
Kailera Therapeutics indicated to open at $24, IPO priced at $16
Kailera Therapeutics (KLRA) priced 39.06M shares at $16.00. The deal size was increased to 39.06M shares from 33.3M and priced at the high end of the $14.00-$16.00 range. JPMorgan, Jefferies, Leerink, TD Cowen and Evercore ISI are acting as joint book running managers for the offering. Kailera is an advanced clinical-stage biotechnology company that says it is “focused on elevating the next era of obesity care.”Introducing TipRanks MCP for Agents Deliver institutional-grade market data directly